Lipocine Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for LPCN, updated each market day.
LPCN AI Sentiment
AI sees no strong directional signal for Lipocine Inc. stock over the next 10 market days.
Prediction date: Sept. 17, 2026
Exact scores are in the SharePreds app
The precise prediction score for this stock, with buy and sell targets and a stop loss, updated every market day.
About Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
Sector
Exchange
Market Cap
$18,302,241
Cap Tier
Employees
14
Headquarters
SALT LAKE CITY, X1
Listed Since
June 5, 2012
Website
LPCN Sentiment Trend: Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
LPCN Volatility
Lipocine Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings: this can present both opportunity and risk for traders.
